OncoMed Pharmaceuticals, Inc. announced that Chairman, President and Chief Executive Officer Paul J. Hastings resigned from the company to pursue new career opportunities, effective January 1st, 2018. The board of directors has retained an executive search firm and has initiated a search for a fulltime successor. In the interim, The Office of the President, comprised of Executive Vice President, Research and Development, John Lewicki, and Executive Vice President and Chief Financial Officer, Sunil Patel, will continue to perform the duties of President and CEO.

In addition, the Board of Directors has appointed Perry Karsen as Chairman of the Board while Jack Lasersohn, formerly Lead Director, remains a Board Member.